Arunesh Verma joins Fresenius Kabi USA as president

Fresenius Kabi is welcoming a new executive. Arunesh Verma has joined the company as president of Fresenius Kabi USA and a member of the company’s global executive leadership team, reporting to Pierluigi Antonelli, CEO of Fresenius Kabi.

Verma is responsible for the commercial operations of Fresenius Kabi in the United States. He succeeds John Ducker, who is retiring after a 35-year career with Fresenius Kabi.

[Read more: Fresenius Kabi intros generic Tepadina]

“I am very pleased to welcome Arunesh Verma to our company at a time when we are successfully executing our #Vision2026 transformation in line with #FutureFresenius, strengthening our commercial operations, and bringing online advanced new U.S. manufacturing capabilities—all designed to support U.S. caregivers,” said Antonelli. “At the same time, I want to thank John Ducker for his outstanding leadership and achievement over 35 years. His contributions have shaped our company’s growth and reputation in the U.S. in profound ways.”

Fresenius Kabi, an operating company of Fresenius, specializes in medicines and technologies for infusion, transfusion and clinical nutrition. In the U.S., Fresenius Kabi plays an essential role in patient care as a leading developer and manufacturer of injectable medicines and biosimilars used in hospitals and other sites of care. The company also is a leader in clinical nutrition and medical technologies that infuse medicines into patients, that collect and process human blood and that enable cell and gene therapies.

“I am thrilled to join Fresenius Kabi, a highly respected global leader with an outstanding reputation in the U.S. and deep roots in health care worldwide,” Verma said. “Fresenius Kabi specializes in putting essential medicines and technologies in the hands of people who care for patients – and this is a purpose to which I have devoted my career of more than 22 years.”

Verma joins Fresenius Kabi from Cipla, a global pharmaceutical company, where he was CEO of Cipla North America and a member of the company’s global Management Council. He started his career as a medical sales representative with Novartis and has held roles of increasing responsibility at Cipla, Torrent Pharma, Sandoz and Dr. Reddy’s Laboratories, where he has led pharmaceutical businesses and functions in the U.S., Central America, Australia and Asia. 

[Read more: Fresenius Kabi intros generic Cytoxan]

Verma holds a master’s degree in business management, marketing and communications from Symbiosis Institute of Business Management and a bachelor’s degree in pharmaceutical sciences, pharmacology and pharmaceutics from the University of Mumbai.